Johnson & Johnson announces new Phase 1b data on bleximenib
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on JNJ:
Disclaimer & DisclosureReport an Issue
RFK Jr. names eight members to vaccine panel, WSJ reports
RFK Jr. names new CDC vaccine advisory panel picks, STAT reports
Johnson & Johnson reports results from Phase 3b APEX study on TREMFYA
Johnson & Johnson Elects Daniel Pinto to Board
Trump Trade: RFK Jr. removes members of vaccine-advising CDC panel
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Los Angeles Times
a day ago
- Los Angeles Times
COVID surges nationwide with highest rates in Southwest as students return to school
COVID-19 rates in the Southwestern United States reached 12.5% — the highest in the nation — according to new data from the U.S. Centers for Disease Control and Prevention released this week. Meanwhile, Los Angeles County recorded the highest COVID levels in its wastewater since February. The spike, thanks to the new highly contagious 'Stratus' variant, comes as students across California return to the classroom, now without a CDC recommendation that they receive updated COVID shots. That change in policy, pushed by Health and Human Services Secretary Robert F. Kennedy Jr., has been criticized by many public health experts. The COVID-19 virus, SARS-CoV-2, mutates often, learning to better transmit itself from person to person and evade immunity created by vaccinations and previous infections. The Stratus variant, first detected in Asia in January, reached the U.S. in March and became the predominant strain by the end of June. It now accounts for two-thirds of virus variants detected in wastewater in the U.S., according to the CDC. The nationwide COVID positivity rate hit 9% in early August, surpassing the January post-holiday surge, but still below last August's spike to 18%. Weekly deaths, a metric that lags behind positivity rates, has so far remained low. In May, RFK Jr. announced the CDC had removed the COVID vaccine from its recommended immunization schedule for healthy children and healthy pregnant women. The secretary argued it was the right move to reverse the Biden administration's policy, which in 2024, 'urged healthy children to get yet another COVID shot, despite the lack of any clinical data to support the repeat booster strategy in children.' That statement promptly spurred a lawsuit from a group of leading medical organizations — including the American Academy of Pediatrics, the American College of Physicians and the American Public Health Association — which argued the 'baseless and uninformed' decision violated federal law by failing to ground the policy on the recommendation of the scientific committee that looks at immunization practices in the U.S. The Advisory Committee on Immunization Practices has been routinely recommending updated COVID vaccinations alongside the typical yearly flu vaccination schedule. In its update for the fall 2024-spring 2025 season, it noted that in the previous year, a COVID booster decreased the risk of hospitalization by 44% and death by 23%. The panel argued the benefit outweighed isolated cases of heart conditions and allergic reactions associated with the vaccine. The panel also acknowledged that booster effectiveness decreases as new COVID strains — for which the boosters were not designed — emerge. Nevertheless, it still felt that most Americans should get booster shots. The CDC estimates that only about 23% of adults and 13% of children received the 2024-2025 COVID booster — even with the vaccine recommendation still in place. That's compared to roughly half of adults and children who received the updated flu shot in the same time frame.
Business Insider
2 days ago
- Business Insider
Precigen Stock (PGEN) Roars Over 60% Higher on FDA Green Light for Papzimeos Therapy
Shares in biopharmaceutical company Precigen (PGEN) rocketed higher today after the U.S. Food and Drug Administration gave the green light to a therapy to treat a rare respiratory disease. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. The approval of the therapy, called Papzimeos, is the first treatment for the condition to receive the health regulator's nod. Fatal Tumors Papzimeos has been approved to treat recurrent respiratory papillomatosis (RRP) — a condition that causes growth of wart-like tumors in the respiratory tract due to human papillomavirus (HPV) infection. RRP can lead to severe voice disturbance, a compromised airway, and recurrent post-obstructive pneumonias. Precigen estimates that there are about 27,000 adult RRP patients in the U.S. RRP can be fatal as there is no cure and the current standard-of-care is repeated surgeries. However, despite being removed in these surgeries, the growth has a tendency to return. 'For more than a century, since RRP was first recognized as a distinct disease, patients have had to rely on repeated surgeries to manage this relentless condition. Today marks a historic turning point. With the landmark FDA approval all adult RRP patients are now eligible for access to the first and only approved therapy that targets the root cause of the disease,' said Helen Sabzevari, PhD, President and CEO of Precigen. Analyst Upgrade Simon Best, associate professor of Otolaryngology at Johns Hopkins Hospital, added: 'Everybody is anxiously awaiting a new treatment for this disease. The patients are and the surgeons are. There's nothing more frustrating than doing a surgery and then having the patient come back six months later.' The approval was based on an early-to-mid-stage study data that showed 51% of patients required no surgeries in the 12 months after the treatment. upgraded Precigen to Neutral from Underweight on the news. It cited the removal of Precigen's 'major regulatory overhang' and its revenue potential for the upgrade. It estimates that peak sales for the drug in the U.S. to be about $250 million. Precigen is certainly making strides when it comes to its financials – as can be seen below. Precigen recently reported a Q2 net loss of $26.6 million, a significant improvement from the $58.8 million loss in the same period last year. Total revenues for the quarter were $856,000, up from $717,000 in the previous year, driven by increased service revenues. Is PGEN a Good Stock to Buy Now? On TipRanks, PGEN has a Hold consensus based on 2 Buy, 1 Hold and 1 Sell ratings. Its highest price target is $6. PGEN stock's consensus price target is $4.50, implying a 143.24% upside.
Time Business News
2 days ago
- Time Business News
Next-Generation Approaches to Hematologic Malignancies
Hematologic malignancies are cancer that affect blood, bone marrow, and lymphatic systems including leukemia, lymphoma and multiple myeloma. These cancers disrupt normal blood cell production and immune function. The growth of the hematologic malignancy market is inspired by increasing the prevalence of global cancer, increasing target remedies and immunotherapy, progression in clinical technologies and expanding research in individual medicine. Additionally, increasing awareness, better healthcare infrastructure, and oncology contribute to more investment market expansion in drug development. Key Growth Drivers and Opportunities Increasing the Prevalence of Global Cancer: The increasing global spread of cancer greatly enhances the growth of the market of hematologic malignancies, as blood -related cancer, such as leukemia, lymphoma and multiple myeloma, become a large part of cancer worldwide. As more individuals are affected by these conditions, there is an increasing demand for accurate diagnosis, advanced treatment options and long -term disease management solutions. In cases, this increase encourages drug companies and research institutes to invest in innovative remedies such as targeted treatment, immunotherapy and CAR-T cell therapy. Additionally, high cancer phenomena motivate governments and healthcare systems to increase screening programs and to reach oncology. Challenges Hematologic malignancies markets face several borders, including high cost of advanced treatments such as car-T cell treatment and targeted drugs, which can restrict access to patients in low- and moderate-income areas. Complex regulatory approval, long clinical testing procedures, and severe side effects or ability to resist also face significant challenges. Additionally, limited availability of specialized clinical equipment and lack of efficient health care professionals in some fields obstruct timely and accurate diagnosis, overall treatment affects results and slows down market development. Innovation and Expansion Kyowa Kirin and Kura Oncology Collaborate to Create Ziftomenib for Acute Leukemias In November 2024, in order to develop and market ziftomenib, Kura's selective oral menin inhibitor, which is being researched for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies, Kura Oncology, Inc. and Kyowa Kirin Co., Ltd. announced they have formed a global strategic partnership. Kura will get USD 330 million up front as part of the deal, and it anticipates receiving up to USD 420 million in near-term milestone payments, including one when ziftomenib is introduced in the monotherapy relapsed/refractory (R/R) context. Merck Launched Phase III Trials for Novel Treatments for Blood Disorders and Cancer In January 2024, With the start of pivotal Phase III studies for four new candidates for solid tumors and hematologic malignancies, Merck's strong oncology and hematology portfolio is progressing. Essential thrombocythemia (ET), small lymphocytic lymphoma (SLL), chronic lymphocytic leukemia (CLL), non-small cell lung cancer (NSCLC), some patients with endometrial carcinoma who have already received treatment, and metastatic castration-resistant prostate cancer (mCRPC) are among the conditions for which the company announced active enrollment for investigational medications. The firm is committed to ongoing research to broaden our portfolio of oncology treatments in order to continue addressing unmet needs in cancer care. The company has a rich history of transforming groundbreaking science into medicines that save and enhance lives worldwide. Inventive Sparks, Expanding Markets The key players operating the hematologic malignancies market includes, Johnson & Johnson Services Inc., Pfizer Inc., Novartis AG, AbbVie Inc., GlaxoSmithKline PLC., Bristol-Myers Squibb Company, Glenmark Pharmaceuticals Inc., Celgene Corporation, F. Hoffman-La Roche Ltd., Takeda Pharmaceutical Company Limited., and others. About Author: Prophecy is a specialized market research, analytics, marketing and business strategy, and solutions company that offer strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high value opportunities in the target business area. Also, we help our client to address business challenges and provide best possible solutions to overcome them and transform their business. TIME BUSINESS NEWS
